Date: 2017-10-19
Type of information: Nomination
Compound:
Company: Pharmaxis (Australia)
Therapeutic area: Fibrotic diseases - Inflammatory diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 19, 2017, Pharmaxis announced several key appointments to further strengthen its capability in drug discovery and development. Following a global search Dr Dieter Hamprecht has been appointed as the Head of Chemistry in the Pharmaxis Drug Discovery team reporting to Department Head Dr Wolfgang Jarolimek. Dr Hamprecht was previously the Managing Director of Boehringer Ingelheim’s research group in Milan. He has a distinguished career as a medicinal chemist having held senior positions at GSK and Boehringer with 37 publications and 44 patents to his name.
- In addition, Pharmaxis has appointed two new members to its Scientific Advisory Board (SAB). Professor Darren Kelly and Dr Kathleen Metters. Professor Kelly is the Associate Dean (Innovation and Enterprise, MDHS) at The University of Melbourne, the Director of Innovation and Enterprise at the Centre for Eye Research Australia (CERA) and Director of
Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne. He was CEO of Fibrotech which was successfully sold to Shire in 2014 and is now the CEO and Managing Director of Australian biotech company OccuRx. He is the entrepreneur in residence at the Medical Research Commercialisation Fund. He has published over 200 manuscripts in the field of translational research and
novel interventions many of which have had a direct impact on human disease.
- Dr Kathleen Metters, PhD, MS, has more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases. She spent 9 years with Merck & Co. including a period as senior vice
president and head of Worldwide Basic Research and leading their External Discovery and Preclinical Sciences. She was subsequently appointed President and Chief Executive Officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer. She was appointed as a non?executive director to the Pharmaxis Board in June 2017.
- Professor Kelly and Dr Metters will join previously appointed members of the Pharmaxis SAB, Professor Andrew Boyle, Professor Jacob George, Professor Carol Pollock and Dr Alan Robertson.
Financial terms:
Latest news:
Is general: Yes
